Maxie Gordon, MD
Psychiatry · Clinton, MSNPI 1427018613
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,114,756 of the $1,309,626 with a category attached, or 85.1%. 22 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 40.8% of the total. Among psychiatry clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,741 payments — averaging $752.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$534K
- Neurocrine Biosciences, Inc.$359K
- Johnson & Johnson$208K
- Alkermes, Inc.$150K
- Teva Pharmaceuticals USA, Inc.$25K
- Sunovion Pharmaceuticals Inc.$18K
- plus $15K from 16 others
Across 3 payments — averaging $7359.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$22K
What the payments were for
- Consulting fees$38,0783%
- Speaking & faculty fees$1,114,75685%
- Travel & lodging$122,6769%
- Food & beverage$33,9653%
- Education$1520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 552 | $534,491 |
| Neurocrine Biosciences, Inc. | 422 | $358,994 |
| Johnson & Johnson | 286 | $207,881 |
| Alkermes, Inc. | 165 | $150,368 |
| Teva Pharmaceuticals USA, Inc. | 51 | $24,846 |
| Sunovion Pharmaceuticals Inc. | 37 | $18,326 |
| Vanda Pharmaceuticals Inc. | 44 | $9,694 |
| Neuronetics, Inc. | 5 | $1,599 |
| AbbVie(2 entities) | 67 | $1,060 |
| Lundbeck LLC | 45 | $654 |
| Otsuka America Pharmaceutical, Inc. | 18 | $441 |
| Janssen Scientific Affairs, LLC | 4 | $374 |
| Indivior Inc. | 16 | $273 |
| Axsome Therapeutics, Inc. | 6 | $185 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $160 |
| E.r. Squibb & Sons, L.L.C. | 5 | $100 |
| Livanova USA, Inc. | 2 | $69 |
| Avanir Pharmaceuticals, Inc. | 3 | $42 |
| Shire North American Group Inc | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Tris Pharma Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$528,206
- ARISTADA$382,984
- INGREZZA$353,557
- LYBALVI$209,743
- INVEGA SUSTENNA$204,424
- INVEGA TRINZA$201,081
- ARISTADA INITIO$95,746
- UZEDY$24,153
- LATUDA$17,924
- Fanapt$8,965
- NEUROSTAR TMS THERAPY SYSTEM$1,559
- SPRAVATO$325
- VRAYLAR$125
- Auvelity$124
- REXULTI$106
How this compares
$1,309,626 in reported general payments places this provider in the 95th percentile of 219 psychiatry providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 16 | $137,135 |
| Invega SustennaPaliperidone Palmitate | 30 | $98,253 |
| CaplytaLumateperone Tosylate | 28 | $48,476 |
| SpravatoEsketamine Hcl | 28 | $33,767 |
| AristadaAripiprazole Lauroxil | 13 | $26,659 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $25,629 |
| RexultiBrexpiprazole | 11 | $17,441 |
| VraylarCariprazine Hcl | 11 | $15,278 |
| Divalproex Sodium | 94 | $1,818 |
| Oxcarbazepine | 41 | $1,772 |
| Aripiprazole | 59 | $1,624 |
| Olanzapine | 60 | $1,166 |
| Mirtazapine | 111 | $789 |
| Clonazepam | 67 | $610 |
| Lurasidone Hcl | 22 | $589 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $358,994 | $137,13516 claims |
| Johnson & JohnsonInvega Sustenna, Spravato | $207,881 | $132,02158 claims |
| Alkermes, Inc.Aristada, Lybalvi | $150,368 | $52,28828 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $534,491 | $48,47628 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $441 | $17,44111 claims |
| AbbVieVraylar | $1,060 | $15,27811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 219 psychiatry providers in Mississippi.
Other psychiatry in Clinton
- Kurt BuechlerRidgeland$1.1M
- Chasity TorrenceWhitfield$834K
- Jon JacksonJackson$834K
- John NortonJackson$173K
- Amy MillerSaltillo$82K
- Clyde GlennRidgeland$68K
- Krishan GuptaJackson$26K
- Joseph KwentusFlowood$13K
- Mark WebbRidgeland$12K
- Kristen BevillJackson$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.